On August 21, 2025, Quanterix Corporation announced that its Accelerator Laboratory was granted a clinical laboratory permit in the Clinical Chemistry category by the New York State Department of Health (NYSDOH). This permit approval expands the laboratory's advanced biomarker research capabilities.
With this permit, the Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. The Simoa NfL Laboratory Developed Test (LDT) specifically gained approval as part of this laboratory permitting.
CEO Masoud Toloue stated that securing this permit reaffirms Quanterix's commitment to quality and compliance, allowing the company to extend its expertise to a broader network of clinical and research partners. The Lucent Diagnostics brand, operating under the Accelerator Laboratory, will now provide advanced serum and plasma biomarker testing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.